Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids

具有前沿检测能力的宽场光学氧化还原成像技术能够评估患者来源的癌症类器官的治疗反应和异质性

阅读:1

Abstract

Patient-derived cancer organoids (PDCO) are a valuable model to recapitulate human disease in culture, with important implications for drug development. However, current methods for rapidly and reproducibly assessing PDCOs are limited. Label-free imaging methods are a promising tool to measure organoid-level heterogeneity and rapidly screen drug responses in PDCOs. This study aimed to assess and predict PDCO response to treatments based on mutational profiles using label-free wide-field optical redox imaging (WF ORI). WF ORI provided organoid-level measurements of treatment response without labels or additional reagents by measuring the autofluorescence intensity of the metabolic coenzymes NAD(P)H and FAD, and the optical redox ratio, defined as the fluorescence intensity of [NAD(P)H/NAD(P)H + FAD], was used to measure the oxidation-reduction state of PDCOs. Development of leading-edge analysis tools helped maximize the sensitivity and reproducibility of treatment response measurements using WF ORI in colorectal cancer PDCOs. Leading-edge analysis improved sensitivity to redox changes in treated PDCOs. Additionally, WF ORI resolved FOLFOX (5-fluorouracil + oxaliplatin) treatment effects across all PDCOs better than two-photon ORI, with an approximately threefold increase in effect size. WF ORI distinguished metabolic differences based on driver mutations in colorectal cancer PDCOs, differentiating between KRAS + PIK3CA double-mutant PDCOs and wild-type PDCOs with 80% accuracy and identified treatment-resistant mutations in mixed PDCO cultures. Overall, WF ORI enables rapid, sensitive, and reproducible measurements of treatment response and heterogeneity in colorectal PDCOs that will affect patient management, clinical trials, and preclinical drug development. SIGNIFICANCE: Label-free wide-field optical redox imaging is an accessible tool for monitoring changes in metabolism in patient-derived cancer organoids to reproducibly assess treatment response and heterogeneity in clinically relevant treatment studies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。